Fish Oil Supplementation and Vascular Function in Hypertensive Patients With Hypertriglyceridemia
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01480687
Verified November 2011 by Mario Fritsch Neves, Hospital Universitario Pedro Ernesto. Recruitment status was: Recruiting
: November 29, 2011
Last Update Posted
: November 29, 2011
Hospital Universitario Pedro Ernesto
Rio de Janeiro State Research Supporting Foundation (FAPERJ)
Information provided by (Responsible Party):
Mario Fritsch Neves, Hospital Universitario Pedro Ernesto
The objective of this study is to compare the effects of ciprofibrate versus omega-3 fatty acid supplementation on the vascular structure and function in hypertensive patients with hypertriglyceridemia.
Condition or disease
Dietary Supplement: DHA-EPADrug: Ciprofibrate
Hypertensive patients aged 40-65 years, both genders, presenting serum triglycerides levels higher than 150 mg/dl will be randomized into two groups. The first group will be receiving ciprofibrate 100mg/day and the second group will be receiving fish oil 1800mg/day. All patients will be evaluated with brachial flow-mediated dilation and with EndoPAT to assess endothelial function before and after supplementation. SPHYGMOCOR and pulse wave velocity (PWV) measurements will also be obtained.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
40 Years to 65 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Previous diagnosis of hypertension
Patients with serum triglycerides levels ≥ 150 mg/dl and <500 mg/dl
Patients on stable antihypertensive medication for at least 4 weeks
Patients with food consumption maintained for at least 4 weeks
Hormone replacement therapy
Chronic kidney disease
Known coronary artery disease
Dyslipidemia severe, with LDL cholesterol> 160 mg/dL or triglycerides ≥ 500 mg/dl